First Author: A.Korol UKRAINE
Co Author(s): V. Naumenko O. Zadorozhnyy I. Nasinnyk 0 0 0 0 0 0 0 0 0
Back to previous
to investigate the efficacy of aflibercept in different subgroups of patients with wet age-related macular degeneration
SI «The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine» (Odesa, Ukraine)
74 patients (79 eyes) with wet AMD received intravitreal injections of 2,0 mg (0,05 ml) aflibercept. All patients were divided into 3 groups. 35 patients (37 eyes) were naïve without treatment (the 1st group), 32 patients (34 eyes) were switched from ranibizumab treatment (the 2nd group) and 7 patients (8 eyes) were switched from bevacizumab treatment (the 3rd group). Patients of the 1st group received aflibercept administered every 4 weeks for the first 3 months, then aflibercept administered every 8 weeks. In the 2nd and the 3rd groups aflibercept administered every 8 weeks from the beginning of the treatment. Patients underwent visometry, optical coherence tomography (OCT) before treatment and at the 1st, 2nd, 3rd, 4th, 6th, 8th of follow up.
in the 1st group mean baseline BCVA was 0.25 (SD; 0.2). At the 8th month it was 0.32 (SD; 0.23) (р=0.0001). In the 2nd group mean BCVA significantly improved from 0.41 (SD; 0.25) to 0.45 (SD; 0.26) (р=0.02). In the 3rd group mean baseline BCVA was 0.2 (range from 0.06 to 0.3). At the 8th month it was 0.25 (range from 0.08 to 0.45). In the 1st group mean retinal thickness in fovea showed a reduction from 351 (SD; 96) microns to 298 (SD; 63) microns (p=0.01). In the 2nd group mean retinal thickness in fovea was 341 (SD; 83) microns. At the 8th month it was 259 (SD; 48) microns (р=0.0001). In the 3rd group mean retinal thickness in fovea reduced from 441 microns (range from 251 to 972microns) to 262 microns (range from 187 to 442 microns).
aflibercept administration got significant increasing of BCVA and decreasing of foveal thickness in naïve patients with wet AMD and in patients with wet AMD who had been switched from ranibizumab. In patients with wet AMD who had been switched from ranibizumab and bevacizumab, aflibercept administration will be expedient every 8 weeks from the beginning of the treatment.